Education
About Us
Working with TipRanks
Follow Us
Kenneth Cunningham Insider Profile
4 Followers
Kenneth Cunningham, Director at Verona Pharma, holds 0.00 shares in Verona Pharma (Ticker: VRNA).
Kenneth Cunningham Verona Pharma (VRNA)Director
Verona Pharma (VRNA)
Director
Not Ranked
Kenneth Cunningham has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Kenneth Cunningham does not currently own shares as a corporate insider.
A breakdown of Kenneth Cunningham's holdings
Insider Roles
Kenneth Cunningham does not currently hold a role as a corporate insider.
Roles that Kenneth Cunningham holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Kenneth Cunningham
Kenneth Cunningham's Trading History
List of latest transactions for each holding click on a transaction to see Kenneth Cunningham's performance on stock
You May Also Like
Kenneth Cunningham insider profile FAQ
What is the percentage of profitable transactions made by Kenneth Cunningham?
The percentage of profitable transactions made by Kenneth Cunningham is ―.
What is the average return per transaction made by Kenneth Cunningham?
The average return per transaction made by Kenneth Cunningham is ―.
What stocks does Kenneth Cunningham hold?
Kenneth Cunningham holds: VRNA stocks.
What was Kenneth Cunningham’s latest transaction?
Kenneth Cunningham latest transaction was an Uninformative Buy of $7.70M.
What was Kenneth Cunningham's most profitable transaction?
Kenneth Cunningham’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Kenneth Cunningham's role in Verona Pharma?
Kenneth Cunningham's role in Verona Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.